New drug combo shows promise against rare, aggressive lymphoma
NCT ID NCT04127227
First seen Mar 16, 2026 · Last updated Jun 17, 2026 · Updated 14 times
Summary
This study tests whether adding the immunotherapy drug Sintilimab to a standard chemotherapy regimen (P-GemOx) can safely and effectively treat people with newly diagnosed, advanced NK/T-cell lymphoma. The trial enrolled 34 adults aged 18-75 who had not received prior treatment. Researchers are measuring how many patients achieve complete remission and how long they live without the cancer progressing.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NK/T CELL LYMPHOMA NOS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 51000, China
Conditions
Explore the condition pages connected to this study.